Skip to Content

Raltegravir Dosage

Applies to the following strength(s): 400 mg ; 25 mg ; 100 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

Film-coated tablets: 400 mg orally twice a day

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Usual Adult Dose for Occupational Exposure

US Public Health Service working group recommendations:
Film-coated tablets: 400 mg orally twice a day
Duration of therapy: 28 days, if tolerated

Comments:
-This drug plus emtricitabine-tenofovir is recommended as the preferred regimen for HIV postexposure prophylaxis; this drug is also recommended as a component in various alternative regimens.
-Prophylaxis should be started as soon as possible, preferably within hours after exposure.
-The optimal duration of prophylaxis is unknown and may differ based on the institution protocol.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Nonoccupational Exposure

US CDC recommendations:
Film-coated tablets: 400 mg orally twice a day
Duration of therapy: 28 days

Comments:
-This drug is recommended as a component of a preferred 3-drug regimen for nonoccupational postexposure prophylaxis of HIV infection; if other alternatives are considered, this drug is recommended as a component in various regimens.
-Prophylaxis should be started as soon as possible, within 72 hours of exposure.
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for HIV Infection

At least 4 weeks of age:
Oral suspension:
3 to less than 4 kg: 20 mg orally twice a day
4 to less than 6 kg: 30 mg orally twice a day
6 to less than 8 kg: 40 mg orally twice a day
8 to less than 11 kg: 60 mg orally twice a day
11 to less than 14 kg: 80 mg orally twice a day
14 to less than 20 kg: 100 mg orally twice a day

Chewable tablets:
11 to less than 14 kg: 75 mg orally twice a day
14 to less than 20 kg: 100 mg orally twice a day
20 to less than 28 kg: 150 mg orally twice a day
28 to less than 40 kg: 200 mg orally twice a day
At least 40 kg: 300 mg orally twice a day

Film-coated tablets:
At least 25 kg: 400 mg orally twice a day

Maximum dose:
-Oral suspension: 100 mg twice a day
-Chewable tablets: 300 mg twice a day

Comments:
-The weight-based dosing recommendation for the oral suspension and chewable tablets is based on about 6 mg/kg/dose twice a day.
-The oral suspension can be used as long as weight is less than 20 kg; either the oral suspension or the chewable tablet formulation can be used for weight between 11 and 20 kg.
-The film-coated tablet is the recommended formulation for patients weighing at least 25 kg; if unable to swallow a tablet, the chewable tablet regimen should be considered.

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Usual Pediatric Dose for Nonoccupational Exposure

US CDC recommendations for pediatric patients at least 4 weeks of age:
Oral suspension:
3 to less than 4 kg: 20 mg orally twice a day
4 to less than 6 kg: 30 mg orally twice a day
6 to less than 8 kg: 40 mg orally twice a day
8 to less than 11 kg: 60 mg orally twice a day
11 to less than 14 kg: 80 mg orally twice a day
14 to less than 20 kg: 100 mg orally twice a day

Chewable tablets:
11 to less than 14 kg: 75 mg orally twice a day
14 to less than 20 kg: 100 mg orally twice a day
20 to less than 28 kg: 150 mg orally twice a day
28 to less than 40 kg: 200 mg orally twice a day
At least 40 kg: 300 mg orally twice a day

Film-coated tablets:
At least 25 kg: 400 mg orally twice a day

Maximum dose:
-Oral suspension: 100 mg twice a day
-Chewable tablets: 300 mg twice a day

Duration of therapy: 28 days

Comments:
-This drug is recommended as a component of a preferred (or alternative) 3-drug regimen for nonoccupational postexposure prophylaxis of HIV infection; if other alternatives are considered, this drug is recommended as a component in various regimens.
-Prophylaxis should be started as soon as possible, within 72 hours of exposure.
-The oral suspension can be used as long as weight is less than 20 kg; either the oral suspension or the chewable tablet formulation can be used for weight between 11 and 20 kg.
-The film-coated tablet is the recommended formulation for patients weighing at least 25 kg; if unable to swallow a tablet, the chewable tablet regimen should be considered.
-Current guidelines should be consulted for additional information.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: Data not available

Dose Adjustments

Concomitant rifampin:
Adults:
-Film-coated tablets: 800 mg orally twice a day

Pediatrics patients (younger than 18 years): Data not available

Precautions

Safety and efficacy have not been established in patients younger than 4 weeks.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:
-Dosing before a dialysis session should be avoided; extent that drug may be dialyzable unknown.

Other Comments

Administration advice:
-May administer without regard to food
-Film-coated tablets: Swallow whole.
-Chewable tablets: May chew or swallow whole.
-Oral suspension: Administer within 30 minutes of mixing.
-Due to lack of bioequivalence, do not substitute the chewable tablets or oral suspension for the 400 mg film-coated tablets.
-Do not use with antacids that contain aluminum and/or magnesium.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Chewable tablets: Store in original package with bottle closed tightly; keep desiccant in bottle to protect from moisture.
-Oral suspension: Store in original container; do not open foil packet until ready for use.

Reconstitution/preparation techniques:
-Oral suspension: The manufacturer product information should be consulted.

General:
-Use with other active agents increases likelihood of treatment response.
-The 25 and 100 mg chewable tablets contain about 0.05 and 0.1 mg phenylalanine, respectively, which can be harmful to patients with phenylketonuria.
-Each single-use packet for oral suspension contains 100 mg of raltegravir; when suspended, the final concentration is 20 mg/mL.

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
-If rash develops, contact healthcare provider at once; if rash develops with fever, general ill feeling, extreme tiredness, muscle/joint aches, blisters, oral lesions, eye inflammation, facial swelling, swelling of the eyes/lips/mouth, difficulty breathing, and/or signs/symptoms of liver problems, stop therapy immediately and seek medical care.
-If unexplained muscle pain, tenderness, or weakness occurs, contact healthcare provider at once.

Hide